Abstract
Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small cell (NSC) cancer MSCs, we identify a key nuclear protein regulator, SFPQ (Splicing Factor Proline and Glutamine Rich), which is overexpressed in lung cancer MSCs and functions to promote MSCs proliferation, chemical resistance, and invasion. Mechanistically, the knockdown of SFPQ reduces CD44v6 expression to inhibit lung cancer MSCs stemness, proliferation in vitro, and metastasis in vivo. The data indicates that SFPQ may be a potential therapeutic target for limiting growth, chemotherapy resistance, and metastasis of lung cancer.
| Original language | English (US) |
|---|---|
| Article number | 862250 |
| Journal | Frontiers in Oncology |
| Volume | 12 |
| DOIs | |
| State | Published - May 30 2022 |
Bibliographical note
Funding Information:The proteomics sample preparation, mass spectrometry analysis, and database searching were performed at the Center for Mass Spectrometry and Proteomics in the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota; supporting agencies are listed here: https://cbs.umn.edu/cmsp/about.
Funding Information:
This work was supported by National Institutes of Health grants R01 HL125227 to CH; R03CA107989 to JL and the Brainstorm Award from the University of Minnesota Cancer Center, 5M Lions International Hearing Foundation to JL.
Publisher Copyright:
Copyright © 2022 Yang, Yang, Jacobson, Gilbertsen, Smith, Higgins, Guerrero, Xia, Henke and Lin.
Keywords
- CD44v6
- SFPQ
- ingenuity pathway analysis
- lung non-small cell (NSC) cancer
- mesenchymal stem cells (MSCs)
- nuclear fraction
- quantitative proteomics
PubMed: MeSH publication types
- Journal Article
